BOSTON, Sept. 22, 2022 (GLOBE NEWSWIRE) -- Aileron Therapeutics (Nasdaq: ALRN), a chemoprotection oncology company that aspires to make chemotherapy...
• Upon closing of their proposed Business Combination, Ocean Biomedical will be a wholly owned subsidiary of Aesther Healthcare Acquisition...
-- Single agent Anti-PD1-IL-2 BiSKIT™ showed superior efficacy compared to a combination of an anti-PD1 antibody with an IL-2 Superkine...
Approximately 40% of Long COVID Patients Experience Multi-Site Pain Similar to Overlapping Chronic Pain Syndromes Fibromyalgia and ME/CFS Approximately 50%...
KRASG12C(ON) Inhibitor with highly differentiated mechanism of action being evaluated in patients with cancers harboring KRASG12C mutation RMC-6291 is first...
WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biopharmaceutical company focused on the...
Initial CPRIT grant funds of $1.9 million to be disbursed to Company by October 31, 2022 CPRIT grant to support...
Testing Times Report reflects expert opinion that “Supporting more widespread use of rapid diagnostic technology should be a central aim...
Phase 1 clinical trial in patients with renal impairment demonstrates balixafortide to be safe and well tolerated Safety findings support...
- Presentation Scheduled for Wednesday, September 28 from 10:40-11:20 AM ET -SAN DIEGO and REDWOOD CITY, Calif., Sept. 21, 2022...
Launching the most ambitious and comprehensive health campaign in British Columbia’s historyOne in two British Columbians will face cancer in...
Live video webcast with moderated roundtable between members of the AIM ImmunoTech Management Team and Key Opinion Leaders Dr. Charles...
Helsinn presents novel data on Chlormethine gel at EORTC cutaneous lymphomas tumors group annual meeting Data on chlormethine in both...
BOSTON, Sept. 21, 2022 (GLOBE NEWSWIRE) -- AVEO Oncology (Nasdaq: AVEO), a commercial stage, oncology-focused biopharmaceutical company committed to delivering...
First patient achieved a confirmed partial response with 51.2% tumor regression with TCR-T cell persistence ongoing at 3 months post...
MIAMI, Sept. 21, 2022 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines for...
The Company’s first Phase 3 trial, OnPrime (GOG-3076), will evaluate Olvi-Vec, a modified vaccinia virus, as immunochemotherapyTrial will be conducted...
Ongoing program to focus on checkpoint inhibitor refractory patients following data presented at ASCO 2022 demonstrating 77% survival at a...
Physician-led network offering complimentary skin cancer screenings across its network of clinics throughout OctoberMAITLAND, Fla., Sept. 20, 2022 (GLOBE NEWSWIRE)...
HAYWARD, Calif., Sept. 20, 2022 (GLOBE NEWSWIRE) -- Predicine, Inc., a global molecular insights company committed to advancing precision medicine...